The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of

Status Not yet recruiting

Clinical Trial Summary

The study is designed to compare Intensity Modulated Radiotherapy (IMRT) in combination with concurrent chemotherapy and IMRT alone in treatment of stage II nasopharyngeal carcinoma.

Clinical Trial Description

Nasopharyngeal carcinoma (NPC) is endemic in Southern China, Southeast Asia, the Arctic, and mid-East/North Africa. NPC prevalence is reported to be highest in southern China, where an average of 80 cases per 100,000 population are reported each year. It is both radiosensitive and chemosensitive. The National Comprehensive Cancer Network (NCCN) guidelines (version 1, 2013), have recommended use of concurrent chemoradiotherapy (CCRT) with or without adjuvant chemotherapy (AC) as standard treatment for NPC.

Recently, the technique of IMRT has become widely used in the treatment of nasopharyngeal carcinoma. The preliminary results showed that IMRT might improve the rate of local control and the quality of life in NPC. In a retrospective study (Ivan,2010), the result showed that IMRT without concurrent chemotherapy provides good outcome for patients with stage IIB NPC with acceptable toxicity. Another study showed that Comparing with IMRT alone, IMRT in combination with chemotherapy provided no significant benefit to locoregionally advanced NPC (Su,2011). With IMRT, it was unclear whether the additional of concurrent chemotherapy was essential for stage II nasopharyngeal carcinoma.

The investigators designed the present study to research the role of adding concurrent chemotherapy to intensity modulated radiotherapy in the treatment of stage II NPC. The primary endpoint is failure-free survival (FFS).The second endpoints were overall survival (OS),loco-regional failure-free survival (LFFS), distant metastasis failure-free survival (DMFS), and acute and late adverse events. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02116231
Study type	Interventional
Source	Cancer Hospital of Guangxi Medical University
Contact	Xiaodong Zhu, Doctor
Email	zhuxiaodong83@163.com
Status	Not yet recruiting
Phase	Phase 2
Start date	April 2014
Completion date	May 2018

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05529940` - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)	Phase 3
Recruiting	`NCT02306837` - Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies	Phase 2
Completed	`NCT02771470` - Intestinal Microflora in Lung Cancer After Chemotherapy	Phase 1
Completed	`NCT02454647` - Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients	N/A
Completed	`NCT02454673` - Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer	N/A
Completed	`NCT01432223` - Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab	Phase 2
Completed	`NCT02767388` - Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Recruiting	`NCT02555592` - Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level	N/A
Suspended	`NCT02121405` - Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM	Phase 3
Recruiting	`NCT02226380` - FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer	Phase 2
Completed	`NCT00911352` - Cryotherapy Intervention for Docetaxel-induced Nail Toxicities	Phase 2/Phase 3
Completed	`NCT03840824` - Blood Spot Self-administered Test and Assay
Active, not recruiting	`NCT01490060` - Fosaprepitant in Patients Receiving Ifosfamide-based Regimen	N/A
Completed	`NCT02395341` - The Longitudinal Ovarian Reserve Study	N/A
Recruiting	`NCT05268991` - Aging and Frailty Study
Recruiting	`NCT03885388` - Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6	Phase 2/Phase 3
Completed	`NCT02375776` - Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention	N/A
Enrolling by invitation	`NCT02074241` - Molecular Markers of Chemosensitivity for Bladder Cancer	N/A
Completed	`NCT01143844` - Assessing Fertility Potential in Female Cancer Survivors
Recruiting	`NCT02169388` - Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms